GPS Wealth Strategies Group LLC Trims Stock Position in Pfizer Inc. (NYSE:PFE)

GPS Wealth Strategies Group LLC reduced its stake in Pfizer Inc. (NYSE:PFE) by 13.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,077 shares of the biopharmaceutical company’s stock after selling 2,475 shares during the quarter. GPS Wealth Strategies Group LLC’s holdings in Pfizer were worth $427,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Quarry LP purchased a new position in Pfizer during the 2nd quarter worth $31,000. Czech National Bank raised its holdings in Pfizer by 6.9% during the third quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock worth $33,407,000 after purchasing an additional 74,737 shares in the last quarter. Quent Capital LLC lifted its position in Pfizer by 15.0% in the third quarter. Quent Capital LLC now owns 15,252 shares of the biopharmaceutical company’s stock valued at $442,000 after purchasing an additional 1,987 shares during the period. GAMMA Investing LLC boosted its holdings in Pfizer by 48.9% in the 3rd quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock valued at $1,155,000 after purchasing an additional 13,097 shares in the last quarter. Finally, Diversified Trust Co increased its position in Pfizer by 33.8% during the 3rd quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock worth $3,285,000 after purchasing an additional 28,658 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. UBS Group reduced their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Truist Financial decreased their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Finally, Guggenheim dropped their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

NYSE PFE opened at $26.51 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The business has a fifty day moving average of $26.27 and a 200-day moving average of $27.86. The stock has a market cap of $150.20 billion, a price-to-earnings ratio of 35.82, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.